Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 1/20 | 0.38 |
| ▸ | CA12 | O43570 | 1/20 | 0.38 |
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
| ▸ | CA7 | P43166 | 1/20 | 0.38 |
| ▸ | CA9 | Q16790 | 1/20 | 0.38 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.38 |
| ▸ | TPSAB1 | Q15661 | 8/20 | 0.37 |
| ▸ | F11 | P03951 | 2/20 | 0.37 |
| ▸ | PARP1 | P09874 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4399108 | 0.85 | PARP1 (0.39) | HSD11B1TPSAB1PARP1 | |
| Hydrochloric Acid SCHEMBL4399052 | 0.81 | TPSAB1 (0.51) | CA12CA1CA2CA7CA9 | |
| SCHEMBL4404678 | 0.81 | GRM5 (0.49) | HSD11B1CA12CA1CA2CA7 | |
| SCHEMBL4406792 | 0.81 | JAK2 (0.41) | HSD11B1TPSAB1 | |
| SCHEMBL4399211 | 0.80 | ACACB (0.46) | PARP1 | |
| SCHEMBL4406915 | 0.79 | LMNA (0.38) | HSD11B1 | |
| SCHEMBL4403349 | 0.79 | LMNA (0.44) | HSD11B1TPSAB1PARP1 | |
| SCHEMBL4397958 | 0.77 | ACACB (0.42) | TPSAB1PARP1 | |
| SCHEMBL4401746 | 0.77 | CCR5 (0.35) | HSD11B1 | |
| SCHEMBL4405962 | 0.77 | GRM5 (0.40) | TPSAB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1296972-B1 | ARYLMETHYLAMINE DERIVATIVES FOR USE AS TRYPTASE INHIBITORS | AVENTIS PHARMA INC (US) | 2009-12-23 | — | — | EP | disclosed |
| US-6977263-B2 | Chemical compounds | AVENTIS PHARMACEUTICALS INC. (US) | 2005-12-20 | — | — | US | disclosed |
| US-20050228018-A1 | Chemical compounds | AVENTIS PHARMACEUTICALS INC. (US) | 2005-10-13 | — | — | US | disclosed |
| US-20030187020-A1 | Chemical compounds | AVENTISUB LLC | 2003-10-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050228018-A1 | Chemical compounds | CMA1, TPSB2, TPSG1 | HSD11B1 925/4885CA12 1714/4885CA1 1776/4885 |
| US-20030187020-A1 | Chemical compounds | CMA1, TPSB2, TPSG1 | HSD11B1 925/4885CA12 1714/4885CA1 1776/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.